In the last week, the United States market has remained flat, yet it has achieved an 8.1% increase over the past year with earnings anticipated to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and expansion within a stable and upward-trending market environment.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 20.31% | 30.44% | ★★★★★★ |
TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
Alkami Technology | 20.45% | 85.16% | ★★★★★★ |
Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
AVITA Medical | 27.74% | 55.36% | ★★★★★★ |
Clene | 61.16% | 59.11% | ★★★★★★ |
TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.76% | 58.08% | ★★★★★★ |
Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 240 stocks from our US High Growth Tech and AI Stocks screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for rare and orphan diseases, with a market cap of $2.30 billion.
Operations: Mirum Pharmaceuticals focuses on developing and commercializing therapies for rare and orphan diseases, generating $336.89 million in revenue from its pharmaceuticals segment.
Mirum Pharmaceuticals, despite its current unprofitability, is navigating a promising trajectory with an expected revenue growth of 21.1% annually, outpacing the US market's 8.4%. This growth is bolstered by its recent FDA approval for Ctexli, a groundbreaking treatment for CTX, highlighting its commitment to addressing rare diseases with significant unmet medical needs. Moreover, the company's R&D focus remains robust as evidenced by substantial investments aimed at expanding its product pipeline and enhancing drug efficacy—crucial steps toward profitability and market relevance in the competitive biotech landscape.
Learn about Mirum Pharmaceuticals' historical performance.
Simply Wall St Growth Rating: ★★★★★★
Overview: Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States and has a market capitalization of approximately $2.71 billion.
Operations: Alkami Technology generates revenue primarily from its Internet Software & Services segment, which accounts for $333.85 million. The company focuses on providing cloud-based digital banking solutions within the U.S. market.
Alkami Technology, Inc. is navigating a transformative path in the digital banking sector, marked by a robust 20.4% annual revenue growth and strategic partnerships aimed at enhancing user experiences and financial security. The company's recent collaboration with BioCatch to thwart $54 million in fraudulent transactions underscores its commitment to innovative fraud prevention techniques. Furthermore, Alkami's R&D investments are pivotal, focusing on integrating cutting-edge technologies to maintain its competitive edge in a rapidly evolving market. This approach not only drives customer satisfaction through improved digital interactions but also positions Alkami for anticipated profitability with an expected earnings growth of 85.16% per year, reflecting its potential resilience and adaptability in the tech landscape.
Evaluate Alkami Technology's historical performance by accessing our past performance report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Intapp, Inc., through its subsidiary Integration Appliance, Inc., offers AI-powered solutions across the United States, the United Kingdom, and internationally with a market cap of approximately $4.84 billion.
Operations: Intapp generates revenue primarily from its Software & Programming segment, amounting to $465.03 million. The company leverages AI-powered solutions to serve clients across various regions, including the United States and the United Kingdom.
Intapp stands out in the tech landscape, notably with its recent unveiling of Intapp DealCloud Activator at their annual event. This AI-driven platform is a game-changer in professional services, enhancing business development through real-time insights and behavioral science to optimize client lifecycle management. The company's commitment to innovation is further evidenced by substantial R&D investments, which have positioned them as a pivotal player in sector modernization. Moreover, the opening of a new R&D center in Lisbon underscores their dedication to global expansion and technological advancement. With revenue up 13.6% annually and an ambitious forecast for profitability within three years, Intapp is strategically poised for sustained growth amidst evolving market demands.
Understand Intapp's track record by examining our Past report.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGM:MIRM NasdaqGS:ALKT and NasdaqGS:INTA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.